Forest Laboratories

Pipeline, Products, Performance, Potential

Publication Date	January 2008
Publisher	Espicom
Product Type	Report
Pages	68
ISBN Number	not applicable
Product Code	ESP00063

Price

£595.00
approximately: $884 | €700

PDF

PRINT £595 ($884 | €700)

Order above formats by FAX

Summary

Forest Laboratories and its subsidiaries develop, manufacture and market branded and generic forms of prescription and non-prescription pharmaceutical products, primarily in the US and Europe. Its major products include Namenda for the treatment of moderate-to-severe Alzheimer's disease, Lexapro for depression and generalised anxiety disorder, Benicar for hypertension and Campral for the maintenance of abstinence from alcohol in patients who are abstinent at treatment initiation.

During fiscal 2006, Forest has attempted to surmount the loss of Celexa, a major product that was selling around US$1,000.0 million before the entry of generics. This revenue reduction has been offset somewhat by sales growth for both Lexapro and Namenda, and an increase in Benicar co-promotion income, consequently, in 2007, Forest achieved earnings growth and record sales. However, the loss of Celexa leaves Forest substantially dependent on the sales of its two principal products, Lexapro and Namenda, which is somewhat risky. In addition, it needs to replace these current products when their exclusivity expires, by expanding its pipeline.

Since Forest lacks the R&D budget of big pharma, its pipeline is dependent on the licensing and acquisition of new product opportunities. However, competition for potential products is high. Although it has had recent success, it does not have the products in place to replace Lexapro and Namenda, so its licensing activity over the next year will be crucial for the company's future. Further, its major agreement with Lundbeck expires in 2010.

The acquisition of Cerexa provides Forest with major opportunities in an entirely new therapeutic area, the hospital injectable anti-infective market, which urgently needs innovative drugs because of the persistent and inevitable development of increased resistance to existing antibiotics; Cerexa's most advanced product, ceftaroline, is now in Phase III studies.

Content

Latest results
Executive Summary
- introduction
- Current Financial Position
  - Company Performance
  - Business Segment Performance
  - Geographic Segment Performance
- Company strategy
  - Mergers, Acquisitions and Divestitures
  - Key Agreements
    - Discontinued Agreements
  - Manufacturing/R&D Infrastructure
  - Products/R&D
  - Employees
- Product Performance Forecasts
- Pipeline analysis
  - Discontinued R&D Projects
- Conclusions/outlook
Therapeutic Area Focus
R&d Pipeline
Central Nervous System
- Marketed Products
  - Campral
  - Lexapro
  - Namenda
  - Others
- R&D Projects
  - mGLUR1/5 antagonists
  - Milnacipran
  - Neramexane
  - Cariprazine
  - RGH-896
- Growth Forecast
Cardiovascular
- Marketed Products
  - Bystolic
  - Others
- R&D Projects
- Growth Forecast
Other
- Marketed Products
- R&D Projects
  - Aclidinium
  - Ceftaroline
  - Linaclotide acetate
  - ME1036
  - Oglemilast
- Growth Forecast
Appendix 1 - Financial Performance
- Full Year results 2007
Appendix 2 - Key Corporate Events
Appendix 3 - Key Agreements
- Almirall Prodesfarma SA
- Aurigene Discovery Technologies Ltd
- Btg Ltd
- Cypress Bioscience Inc
- Daiichi Sankyo
- Gedeon Richter Ltd
- Glenmark Pharmaceuticals Ltd
- Ino Therapeutics
- Lundbeck
- Merck KGaA
- Merz Pharma GmbH & Co KGaA
- Microbia Inc
- Mylan Laboratories Inc
- Novexel
- Recordati
- Procter & Gamble
- Samaritan Pharmaceuticals Inc
Appendix 4 - Infrastructure
- research and Development Facilities
- Manufacturing Facilities
Appendix 5 - Key Pharmaceutical
Subsidiaries
Index of Tables
- Principal Operating Results
- Sales Breakdown
- Pharmaceutical Sales by Geographic Area
- Long-Lived Assets
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Central Nervous System Products, 2007
Index of Charts
- Sales Breakdown, 2007
- Pharmaceutical Sales by Geographic Area, 2007
- Sales of Major Products (2001A-2011E)
- Top Selling Products, 2007
- Campral Sales (2002A-2012E)
- Lexapro Sales (2002A-2012E)
- Namenda Sales (2002-2012E)
- Milnacipran Sales (2008E-2015E)
- Neramexane Sales (2009E-2011E)
- Nebivolol Sales (2008E-2015E)
- Aclidinium Sales (2009E-2015E)
- Sales, Costs and Operating Income
  - Forest Laboratories
  - Profitability and Research Ratios
  - R&D Expenditure and Capital Expenditure
  - Current Assets, Liabilities and Ratio
  - Assets, Cash and Liquidity
  - Employees and Productivity